Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA‐1273 as a third dose in solid organ transplant recipients seronegative after two‐dose mRNA vaccination
Heterologous vaccination (“mixing platforms”) for the third (D3) dose of SARS‐CoV‐2 vaccine is a potential strategy to improve antibody responses in solid organ transplant recipients (SOTRs), but data are mixed regarding potential differential immunogenicity. We assessed for differences in immunogen...
Gespeichert in:
| Veröffentlicht in: | American journal of transplantation 2022-09, Vol.22 (9), p.2254-2260 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2260 |
|---|---|
| container_issue | 9 |
| container_start_page | 2254 |
| container_title | American journal of transplantation |
| container_volume | 22 |
| creator | Chiang, Teresa PY Alejo, Jennifer L. Mitchell, Jonathan Kim, Jake D. Abedon, Aura T. Karaba, Andrew H. Thomas, Letitia Levan, Macey L. Garonzik‐Wang, Jacqueline M. Avery, Robin K. Pekosz, Andrew Clarke, William A. Warren, Daniel S. Tobian, Aaron A. R. Massie, Allan B. Segev, Dorry L. Werbel, William A. |
| description | Heterologous vaccination (“mixing platforms”) for the third (D3) dose of SARS‐CoV‐2 vaccine is a potential strategy to improve antibody responses in solid organ transplant recipients (SOTRs), but data are mixed regarding potential differential immunogenicity. We assessed for differences in immunogenicity and tolerability of homologous (BNT162b2 or mRNA‐1273; D3‐mRNA) versus heterologous (Ad.26.COV2.S; D3‐JJ) D3 among 377 SARS‐CoV‐2‐infection naïve SOTRs who remained seronegative after two mRNA vaccines. We measured anti‐spike titers and used weighted Poisson regression to evaluate seroconversion and development of high‐titers, comparing D3‐JJ to D3‐mRNA, at 1‐, 3‐, and 6 month post‐D3. 1‐month post‐D3, seroconversion (63% vs. 52%, p = .3) and development of high‐titers (29% vs. 25%, p = .7) were comparable between D3‐JJ and D3‐mRNA recipients. 3 month post‐D3, D3‐JJ recipients were 1.4‐fold more likely to seroconvert (80% vs. 57%, weighted incidence‐rate‐ratio: wIRR = 1.101.401.77, p = .006) but not more likely to develop high‐titers (27% vs. 22%, wIRR = 0.440.921.93, p = .8). 6 month post‐D3, D3‐JJ recipients were 1.41‐fold more likely to seroconvert (88% vs. 59%, wIRR = 1.04 1.411.93, p = .029) and 2.63‐fold more likely to develop high‐titers (59% vs. 21%, wIRR = 1.382.635.00, p = .003). There was no differential signal in alloimmune events or reactogenicity between platforms. SOTRs without antibody response after two mRNA vaccines may derive benefit from heterologous Ad.26.COV2.S D3.
Solid organ transplant recipients with negative anti‐spike antibody after a two‐dose mRNA SARS‐CoV‐2 vaccine series are more likely to seroconvert after receiving a third dose of the heterologous vaccine Ad.26.COV2.S, compared to a homologous mRNA vaccine. |
| doi_str_mv | 10.1111/ajt.17061 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9111240</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2707779702</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4431-af7ba6498b8fc96b604ac2ed8be881c77d22a356f0d9e317e884744dba07fdf83</originalsourceid><addsrcrecordid>eNp1kc1uEzEURi0Eoj-w4AWQJVYsMrE9jj2zQQoRUFDVShDYWndsT-JoYqe2k6q7PgIPwZPxJLhNG8ECb2xdH537SR9CryipaDljWOWKSiLoE3RMBSEjQXn99PCuJ0foJKUVIVSyhj1HR_WEs5ZReox-ndlsYxjCImwTnpqKiWp2-YNV3_DOxlRmy7B-_H5_MaeCdWy8_nox_X37kzJZY0gYcF66aLAJyWLncQqDMzjEBXicI_i0GcBnHK12G2d9TjiVnd4uILudxdCXCDhfh6K8V9zp8Q60dr4Qwb9Az3oYkn35cJ-i7x8_zGdno_PLT59n0_OR5rymI-hlB4K3Tdf0uhWdIBw0s6bpbNNQLaVhDOqJ6IlpbU1lmXLJuemAyN70TX2K3u29m223tkaXqBEGtYluDfFGBXDq3x_vlmoRdqotLTBOiuDNgyCGq61NWa3CNvqSWTFJpJStJKxQb_eUjiGlaPvDBkrUXaGqFKruCy3s678jHcjHBgsw3gPXbrA3_zep6Zf5XvkHqZWt5g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2707779702</pqid></control><display><type>article</type><title>Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA‐1273 as a third dose in solid organ transplant recipients seronegative after two‐dose mRNA vaccination</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Chiang, Teresa PY ; Alejo, Jennifer L. ; Mitchell, Jonathan ; Kim, Jake D. ; Abedon, Aura T. ; Karaba, Andrew H. ; Thomas, Letitia ; Levan, Macey L. ; Garonzik‐Wang, Jacqueline M. ; Avery, Robin K. ; Pekosz, Andrew ; Clarke, William A. ; Warren, Daniel S. ; Tobian, Aaron A. R. ; Massie, Allan B. ; Segev, Dorry L. ; Werbel, William A.</creator><creatorcontrib>Chiang, Teresa PY ; Alejo, Jennifer L. ; Mitchell, Jonathan ; Kim, Jake D. ; Abedon, Aura T. ; Karaba, Andrew H. ; Thomas, Letitia ; Levan, Macey L. ; Garonzik‐Wang, Jacqueline M. ; Avery, Robin K. ; Pekosz, Andrew ; Clarke, William A. ; Warren, Daniel S. ; Tobian, Aaron A. R. ; Massie, Allan B. ; Segev, Dorry L. ; Werbel, William A.</creatorcontrib><description>Heterologous vaccination (“mixing platforms”) for the third (D3) dose of SARS‐CoV‐2 vaccine is a potential strategy to improve antibody responses in solid organ transplant recipients (SOTRs), but data are mixed regarding potential differential immunogenicity. We assessed for differences in immunogenicity and tolerability of homologous (BNT162b2 or mRNA‐1273; D3‐mRNA) versus heterologous (Ad.26.COV2.S; D3‐JJ) D3 among 377 SARS‐CoV‐2‐infection naïve SOTRs who remained seronegative after two mRNA vaccines. We measured anti‐spike titers and used weighted Poisson regression to evaluate seroconversion and development of high‐titers, comparing D3‐JJ to D3‐mRNA, at 1‐, 3‐, and 6 month post‐D3. 1‐month post‐D3, seroconversion (63% vs. 52%, p = .3) and development of high‐titers (29% vs. 25%, p = .7) were comparable between D3‐JJ and D3‐mRNA recipients. 3 month post‐D3, D3‐JJ recipients were 1.4‐fold more likely to seroconvert (80% vs. 57%, weighted incidence‐rate‐ratio: wIRR = 1.101.401.77, p = .006) but not more likely to develop high‐titers (27% vs. 22%, wIRR = 0.440.921.93, p = .8). 6 month post‐D3, D3‐JJ recipients were 1.41‐fold more likely to seroconvert (88% vs. 59%, wIRR = 1.04 1.411.93, p = .029) and 2.63‐fold more likely to develop high‐titers (59% vs. 21%, wIRR = 1.382.635.00, p = .003). There was no differential signal in alloimmune events or reactogenicity between platforms. SOTRs without antibody response after two mRNA vaccines may derive benefit from heterologous Ad.26.COV2.S D3.
Solid organ transplant recipients with negative anti‐spike antibody after a two‐dose mRNA SARS‐CoV‐2 vaccine series are more likely to seroconvert after receiving a third dose of the heterologous vaccine Ad.26.COV2.S, compared to a homologous mRNA vaccine.</description><identifier>ISSN: 1600-6135</identifier><identifier>EISSN: 1600-6143</identifier><identifier>DOI: 10.1111/ajt.17061</identifier><identifier>PMID: 35429211</identifier><language>eng</language><publisher>United States: Elsevier Limited</publisher><subject>2019-nCoV Vaccine mRNA-1273 - adverse effects ; antibodies ; Antibodies, Viral ; Antibody response ; BNT162 Vaccine - adverse effects ; Brief Communication ; COVID-19 - epidemiology ; COVID-19 - prevention & control ; COVID-19 vaccines ; COVID-19 Vaccines - adverse effects ; heterologous ; Humans ; Immunization ; Immunogenicity ; Influenza Vaccines ; mRNA ; mRNA vaccines ; Organ Transplantation - adverse effects ; RNA, Messenger - genetics ; SARS-CoV-2 ; Seroconversion ; Severe acute respiratory syndrome coronavirus 2 ; transplant ; Transplant Recipients ; Transplants & implants ; Vaccination ; vaccine</subject><ispartof>American journal of transplantation, 2022-09, Vol.22 (9), p.2254-2260</ispartof><rights>2022 The Authors. published by Wiley Periodicals LLC on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons</rights><rights>2022 The Authors. American Journal of Transplantation published by Wiley Periodicals LLC on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons.</rights><rights>2022. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4431-af7ba6498b8fc96b604ac2ed8be881c77d22a356f0d9e317e884744dba07fdf83</citedby><cites>FETCH-LOGICAL-c4431-af7ba6498b8fc96b604ac2ed8be881c77d22a356f0d9e317e884744dba07fdf83</cites><orcidid>0000-0002-0517-3766 ; 0000-0003-3248-1761 ; 0000-0003-0601-7420 ; 0000-0003-0418-3636 ; 0000-0001-9665-4786 ; 0000-0001-8083-6964 ; 0000-0002-6323-2285 ; 0000-0002-1924-4801 ; 0000-0002-5288-5125 ; 0000-0003-2785-317X ; 0000-0002-4239-1252 ; 0000-0003-2943-5895 ; 0000-0003-3137-9271 ; 0000-0002-2789-7503 ; 0000-0001-7692-3619 ; 0000-0002-7667-8075 ; 0000-0002-1370-466X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fajt.17061$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fajt.17061$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35429211$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chiang, Teresa PY</creatorcontrib><creatorcontrib>Alejo, Jennifer L.</creatorcontrib><creatorcontrib>Mitchell, Jonathan</creatorcontrib><creatorcontrib>Kim, Jake D.</creatorcontrib><creatorcontrib>Abedon, Aura T.</creatorcontrib><creatorcontrib>Karaba, Andrew H.</creatorcontrib><creatorcontrib>Thomas, Letitia</creatorcontrib><creatorcontrib>Levan, Macey L.</creatorcontrib><creatorcontrib>Garonzik‐Wang, Jacqueline M.</creatorcontrib><creatorcontrib>Avery, Robin K.</creatorcontrib><creatorcontrib>Pekosz, Andrew</creatorcontrib><creatorcontrib>Clarke, William A.</creatorcontrib><creatorcontrib>Warren, Daniel S.</creatorcontrib><creatorcontrib>Tobian, Aaron A. R.</creatorcontrib><creatorcontrib>Massie, Allan B.</creatorcontrib><creatorcontrib>Segev, Dorry L.</creatorcontrib><creatorcontrib>Werbel, William A.</creatorcontrib><title>Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA‐1273 as a third dose in solid organ transplant recipients seronegative after two‐dose mRNA vaccination</title><title>American journal of transplantation</title><addtitle>Am J Transplant</addtitle><description>Heterologous vaccination (“mixing platforms”) for the third (D3) dose of SARS‐CoV‐2 vaccine is a potential strategy to improve antibody responses in solid organ transplant recipients (SOTRs), but data are mixed regarding potential differential immunogenicity. We assessed for differences in immunogenicity and tolerability of homologous (BNT162b2 or mRNA‐1273; D3‐mRNA) versus heterologous (Ad.26.COV2.S; D3‐JJ) D3 among 377 SARS‐CoV‐2‐infection naïve SOTRs who remained seronegative after two mRNA vaccines. We measured anti‐spike titers and used weighted Poisson regression to evaluate seroconversion and development of high‐titers, comparing D3‐JJ to D3‐mRNA, at 1‐, 3‐, and 6 month post‐D3. 1‐month post‐D3, seroconversion (63% vs. 52%, p = .3) and development of high‐titers (29% vs. 25%, p = .7) were comparable between D3‐JJ and D3‐mRNA recipients. 3 month post‐D3, D3‐JJ recipients were 1.4‐fold more likely to seroconvert (80% vs. 57%, weighted incidence‐rate‐ratio: wIRR = 1.101.401.77, p = .006) but not more likely to develop high‐titers (27% vs. 22%, wIRR = 0.440.921.93, p = .8). 6 month post‐D3, D3‐JJ recipients were 1.41‐fold more likely to seroconvert (88% vs. 59%, wIRR = 1.04 1.411.93, p = .029) and 2.63‐fold more likely to develop high‐titers (59% vs. 21%, wIRR = 1.382.635.00, p = .003). There was no differential signal in alloimmune events or reactogenicity between platforms. SOTRs without antibody response after two mRNA vaccines may derive benefit from heterologous Ad.26.COV2.S D3.
Solid organ transplant recipients with negative anti‐spike antibody after a two‐dose mRNA SARS‐CoV‐2 vaccine series are more likely to seroconvert after receiving a third dose of the heterologous vaccine Ad.26.COV2.S, compared to a homologous mRNA vaccine.</description><subject>2019-nCoV Vaccine mRNA-1273 - adverse effects</subject><subject>antibodies</subject><subject>Antibodies, Viral</subject><subject>Antibody response</subject><subject>BNT162 Vaccine - adverse effects</subject><subject>Brief Communication</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 vaccines</subject><subject>COVID-19 Vaccines - adverse effects</subject><subject>heterologous</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunogenicity</subject><subject>Influenza Vaccines</subject><subject>mRNA</subject><subject>mRNA vaccines</subject><subject>Organ Transplantation - adverse effects</subject><subject>RNA, Messenger - genetics</subject><subject>SARS-CoV-2</subject><subject>Seroconversion</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>transplant</subject><subject>Transplant Recipients</subject><subject>Transplants & implants</subject><subject>Vaccination</subject><subject>vaccine</subject><issn>1600-6135</issn><issn>1600-6143</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1kc1uEzEURi0Eoj-w4AWQJVYsMrE9jj2zQQoRUFDVShDYWndsT-JoYqe2k6q7PgIPwZPxJLhNG8ECb2xdH537SR9CryipaDljWOWKSiLoE3RMBSEjQXn99PCuJ0foJKUVIVSyhj1HR_WEs5ZReox-ndlsYxjCImwTnpqKiWp2-YNV3_DOxlRmy7B-_H5_MaeCdWy8_nox_X37kzJZY0gYcF66aLAJyWLncQqDMzjEBXicI_i0GcBnHK12G2d9TjiVnd4uILudxdCXCDhfh6K8V9zp8Q60dr4Qwb9Az3oYkn35cJ-i7x8_zGdno_PLT59n0_OR5rymI-hlB4K3Tdf0uhWdIBw0s6bpbNNQLaVhDOqJ6IlpbU1lmXLJuemAyN70TX2K3u29m223tkaXqBEGtYluDfFGBXDq3x_vlmoRdqotLTBOiuDNgyCGq61NWa3CNvqSWTFJpJStJKxQb_eUjiGlaPvDBkrUXaGqFKruCy3s678jHcjHBgsw3gPXbrA3_zep6Zf5XvkHqZWt5g</recordid><startdate>202209</startdate><enddate>202209</enddate><creator>Chiang, Teresa PY</creator><creator>Alejo, Jennifer L.</creator><creator>Mitchell, Jonathan</creator><creator>Kim, Jake D.</creator><creator>Abedon, Aura T.</creator><creator>Karaba, Andrew H.</creator><creator>Thomas, Letitia</creator><creator>Levan, Macey L.</creator><creator>Garonzik‐Wang, Jacqueline M.</creator><creator>Avery, Robin K.</creator><creator>Pekosz, Andrew</creator><creator>Clarke, William A.</creator><creator>Warren, Daniel S.</creator><creator>Tobian, Aaron A. R.</creator><creator>Massie, Allan B.</creator><creator>Segev, Dorry L.</creator><creator>Werbel, William A.</creator><general>Elsevier Limited</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0517-3766</orcidid><orcidid>https://orcid.org/0000-0003-3248-1761</orcidid><orcidid>https://orcid.org/0000-0003-0601-7420</orcidid><orcidid>https://orcid.org/0000-0003-0418-3636</orcidid><orcidid>https://orcid.org/0000-0001-9665-4786</orcidid><orcidid>https://orcid.org/0000-0001-8083-6964</orcidid><orcidid>https://orcid.org/0000-0002-6323-2285</orcidid><orcidid>https://orcid.org/0000-0002-1924-4801</orcidid><orcidid>https://orcid.org/0000-0002-5288-5125</orcidid><orcidid>https://orcid.org/0000-0003-2785-317X</orcidid><orcidid>https://orcid.org/0000-0002-4239-1252</orcidid><orcidid>https://orcid.org/0000-0003-2943-5895</orcidid><orcidid>https://orcid.org/0000-0003-3137-9271</orcidid><orcidid>https://orcid.org/0000-0002-2789-7503</orcidid><orcidid>https://orcid.org/0000-0001-7692-3619</orcidid><orcidid>https://orcid.org/0000-0002-7667-8075</orcidid><orcidid>https://orcid.org/0000-0002-1370-466X</orcidid></search><sort><creationdate>202209</creationdate><title>Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA‐1273 as a third dose in solid organ transplant recipients seronegative after two‐dose mRNA vaccination</title><author>Chiang, Teresa PY ; Alejo, Jennifer L. ; Mitchell, Jonathan ; Kim, Jake D. ; Abedon, Aura T. ; Karaba, Andrew H. ; Thomas, Letitia ; Levan, Macey L. ; Garonzik‐Wang, Jacqueline M. ; Avery, Robin K. ; Pekosz, Andrew ; Clarke, William A. ; Warren, Daniel S. ; Tobian, Aaron A. R. ; Massie, Allan B. ; Segev, Dorry L. ; Werbel, William A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4431-af7ba6498b8fc96b604ac2ed8be881c77d22a356f0d9e317e884744dba07fdf83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>2019-nCoV Vaccine mRNA-1273 - adverse effects</topic><topic>antibodies</topic><topic>Antibodies, Viral</topic><topic>Antibody response</topic><topic>BNT162 Vaccine - adverse effects</topic><topic>Brief Communication</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 vaccines</topic><topic>COVID-19 Vaccines - adverse effects</topic><topic>heterologous</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunogenicity</topic><topic>Influenza Vaccines</topic><topic>mRNA</topic><topic>mRNA vaccines</topic><topic>Organ Transplantation - adverse effects</topic><topic>RNA, Messenger - genetics</topic><topic>SARS-CoV-2</topic><topic>Seroconversion</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>transplant</topic><topic>Transplant Recipients</topic><topic>Transplants & implants</topic><topic>Vaccination</topic><topic>vaccine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chiang, Teresa PY</creatorcontrib><creatorcontrib>Alejo, Jennifer L.</creatorcontrib><creatorcontrib>Mitchell, Jonathan</creatorcontrib><creatorcontrib>Kim, Jake D.</creatorcontrib><creatorcontrib>Abedon, Aura T.</creatorcontrib><creatorcontrib>Karaba, Andrew H.</creatorcontrib><creatorcontrib>Thomas, Letitia</creatorcontrib><creatorcontrib>Levan, Macey L.</creatorcontrib><creatorcontrib>Garonzik‐Wang, Jacqueline M.</creatorcontrib><creatorcontrib>Avery, Robin K.</creatorcontrib><creatorcontrib>Pekosz, Andrew</creatorcontrib><creatorcontrib>Clarke, William A.</creatorcontrib><creatorcontrib>Warren, Daniel S.</creatorcontrib><creatorcontrib>Tobian, Aaron A. R.</creatorcontrib><creatorcontrib>Massie, Allan B.</creatorcontrib><creatorcontrib>Segev, Dorry L.</creatorcontrib><creatorcontrib>Werbel, William A.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chiang, Teresa PY</au><au>Alejo, Jennifer L.</au><au>Mitchell, Jonathan</au><au>Kim, Jake D.</au><au>Abedon, Aura T.</au><au>Karaba, Andrew H.</au><au>Thomas, Letitia</au><au>Levan, Macey L.</au><au>Garonzik‐Wang, Jacqueline M.</au><au>Avery, Robin K.</au><au>Pekosz, Andrew</au><au>Clarke, William A.</au><au>Warren, Daniel S.</au><au>Tobian, Aaron A. R.</au><au>Massie, Allan B.</au><au>Segev, Dorry L.</au><au>Werbel, William A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA‐1273 as a third dose in solid organ transplant recipients seronegative after two‐dose mRNA vaccination</atitle><jtitle>American journal of transplantation</jtitle><addtitle>Am J Transplant</addtitle><date>2022-09</date><risdate>2022</risdate><volume>22</volume><issue>9</issue><spage>2254</spage><epage>2260</epage><pages>2254-2260</pages><issn>1600-6135</issn><eissn>1600-6143</eissn><abstract>Heterologous vaccination (“mixing platforms”) for the third (D3) dose of SARS‐CoV‐2 vaccine is a potential strategy to improve antibody responses in solid organ transplant recipients (SOTRs), but data are mixed regarding potential differential immunogenicity. We assessed for differences in immunogenicity and tolerability of homologous (BNT162b2 or mRNA‐1273; D3‐mRNA) versus heterologous (Ad.26.COV2.S; D3‐JJ) D3 among 377 SARS‐CoV‐2‐infection naïve SOTRs who remained seronegative after two mRNA vaccines. We measured anti‐spike titers and used weighted Poisson regression to evaluate seroconversion and development of high‐titers, comparing D3‐JJ to D3‐mRNA, at 1‐, 3‐, and 6 month post‐D3. 1‐month post‐D3, seroconversion (63% vs. 52%, p = .3) and development of high‐titers (29% vs. 25%, p = .7) were comparable between D3‐JJ and D3‐mRNA recipients. 3 month post‐D3, D3‐JJ recipients were 1.4‐fold more likely to seroconvert (80% vs. 57%, weighted incidence‐rate‐ratio: wIRR = 1.101.401.77, p = .006) but not more likely to develop high‐titers (27% vs. 22%, wIRR = 0.440.921.93, p = .8). 6 month post‐D3, D3‐JJ recipients were 1.41‐fold more likely to seroconvert (88% vs. 59%, wIRR = 1.04 1.411.93, p = .029) and 2.63‐fold more likely to develop high‐titers (59% vs. 21%, wIRR = 1.382.635.00, p = .003). There was no differential signal in alloimmune events or reactogenicity between platforms. SOTRs without antibody response after two mRNA vaccines may derive benefit from heterologous Ad.26.COV2.S D3.
Solid organ transplant recipients with negative anti‐spike antibody after a two‐dose mRNA SARS‐CoV‐2 vaccine series are more likely to seroconvert after receiving a third dose of the heterologous vaccine Ad.26.COV2.S, compared to a homologous mRNA vaccine.</abstract><cop>United States</cop><pub>Elsevier Limited</pub><pmid>35429211</pmid><doi>10.1111/ajt.17061</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-0517-3766</orcidid><orcidid>https://orcid.org/0000-0003-3248-1761</orcidid><orcidid>https://orcid.org/0000-0003-0601-7420</orcidid><orcidid>https://orcid.org/0000-0003-0418-3636</orcidid><orcidid>https://orcid.org/0000-0001-9665-4786</orcidid><orcidid>https://orcid.org/0000-0001-8083-6964</orcidid><orcidid>https://orcid.org/0000-0002-6323-2285</orcidid><orcidid>https://orcid.org/0000-0002-1924-4801</orcidid><orcidid>https://orcid.org/0000-0002-5288-5125</orcidid><orcidid>https://orcid.org/0000-0003-2785-317X</orcidid><orcidid>https://orcid.org/0000-0002-4239-1252</orcidid><orcidid>https://orcid.org/0000-0003-2943-5895</orcidid><orcidid>https://orcid.org/0000-0003-3137-9271</orcidid><orcidid>https://orcid.org/0000-0002-2789-7503</orcidid><orcidid>https://orcid.org/0000-0001-7692-3619</orcidid><orcidid>https://orcid.org/0000-0002-7667-8075</orcidid><orcidid>https://orcid.org/0000-0002-1370-466X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1600-6135 |
| ispartof | American journal of transplantation, 2022-09, Vol.22 (9), p.2254-2260 |
| issn | 1600-6135 1600-6143 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9111240 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | 2019-nCoV Vaccine mRNA-1273 - adverse effects antibodies Antibodies, Viral Antibody response BNT162 Vaccine - adverse effects Brief Communication COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - adverse effects heterologous Humans Immunization Immunogenicity Influenza Vaccines mRNA mRNA vaccines Organ Transplantation - adverse effects RNA, Messenger - genetics SARS-CoV-2 Seroconversion Severe acute respiratory syndrome coronavirus 2 transplant Transplant Recipients Transplants & implants Vaccination vaccine |
| title | Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA‐1273 as a third dose in solid organ transplant recipients seronegative after two‐dose mRNA vaccination |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T17%3A33%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Heterologous%20Ad.26.COV2.S%20versus%20homologous%20BNT162b2/mRNA%E2%80%901273%20as%20a%20third%20dose%20in%20solid%20organ%20transplant%20recipients%20seronegative%20after%20two%E2%80%90dose%20mRNA%20vaccination&rft.jtitle=American%20journal%20of%20transplantation&rft.au=Chiang,%20Teresa%20PY&rft.date=2022-09&rft.volume=22&rft.issue=9&rft.spage=2254&rft.epage=2260&rft.pages=2254-2260&rft.issn=1600-6135&rft.eissn=1600-6143&rft_id=info:doi/10.1111/ajt.17061&rft_dat=%3Cproquest_pubme%3E2707779702%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2707779702&rft_id=info:pmid/35429211&rfr_iscdi=true |